Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. [electronic resource] by
- Yeung, D T
- Moulton, D J
- Heatley, S L
- Nievergall, E
- Dang, P
- Braley, J
- Branford, S
- Moore, S
- Mullighan, C G
- Hughes, T P
- White, D L
Producer: 20150324
In:
Leukemia vol. 29
Availability: No items available.
|
|
9.
|
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. [electronic resource] by
- Nievergall, E
- Reynolds, J
- Kok, C H
- Watkins, D B
- Biondo, M
- Busfield, S J
- Vairo, G
- Fuller, K
- Erber, W N
- Sadras, T
- Grose, R
- Yeung, D T
- Lopez, A F
- Hiwase, D K
- Hughes, T P
- White, D L
Producer: 20170829
In:
Leukemia vol. 30
Availability: No items available.
|
|
10.
|
Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes. [electronic resource] by
- Chong, C-E
- Venugopal, P
- Stokes, P H
- Lee, Y K
- Brautigan, P J
- Yeung, D T O
- Babic, M
- Engler, G A
- Lane, S W
- Klingler-Hoffmann, M
- Matthews, J M
- D'Andrea, R J
- Brown, A L
- Hahn, C N
- Scott, H S
Producer: 20181211
In:
Leukemia vol. 32
Availability: No items available.
|